Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
By increasing resting energy expenditure through thermogenesis and fat oxidation, retatrutide may promote preferential fat loss while relatively sparing lean mass
Beyond weight outcomes, the Phase 2 obesity trial also reported improvements in several cardiometabolic markers, including: Reductions in waist circumference Improvements in fasting glucose and insulin sensitivity Favourable changes in blood pressure and lipid profiles Phase 3 trials understood to form part of the TRIUMPH programme are now underway, evaluating retatrutide in broader populations including people with type 2 diabetes and cardiovascular disease
Both are weekly injectable therapies that work on incretin hormone pathways associated with hunger and blood sugar regulation
Most content covering this stack falls into one of two categories
McGovern AS, Hamlin AS, Winter G
